Finance

Lists
TEVA:NYSE
Teva Pharmaceutical Industries Limited
$ 40.72
-1.28%
(-0.53) 1D
$ 40.75
+0.07% (+0.030)
After hours
Closed: 10-р сарын 14, 16:00:02 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Open
$ 41.11
High
$ 41.87
Low
$ 40.71
Mkt. cap
46.68 тэрбум
Avg. vol.
5.65 сая
Volume
10.27 сая
52-wk high
$ 42.02
52-wk low
$ 18.82
Beta
1.07
Shares outstanding
1.17 тэрбум
No. of employees
32 мян
Open
$ 41.11
High
$ 41.87
Low
$ 40.71
Mkt. cap
46.68 тэрбум
Avg. vol.
5.65 сая
Volume
10.27 сая
52-wk high
$ 42.02
52-wk low
$ 18.82
Beta
1.07
Shares outstanding
1.17 тэрбум
No. of employees
32 мян
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited
CEORichard Francis
Employees32 мян
Founded1944 оны 2-р сарын 13
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Analyst ratings
Based on 9 analysts giving stock ratings to TEVA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for TEVA in the last 3 months.
Highest
Current $ 40.72
$ 50.00 (+22.79%)
Average
$ 44.00 (+8.06%)
Lowest
$ 40.00 (-1.77%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Buy
Initiated
$ 45.00
+10.5%
09/09/2026
Ashwani Verma
UBS
Buy
Maintained
$ 48.00
+17.9%
09/04/2026
Dennis Ding
Jefferies
Buy
Maintained
$ 40.00
-1.8%
09/03/2026
Louise Chen
Scotiabank
Buy
Maintained
$ 40.00
-1.8%
09/03/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$ 50.00
+22.8%
09/02/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$ 43.00
+5.6%
09/02/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
09/02/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$ 44.00
+8.1%
08/27/2026
Glen Santangelo
Barclays
Buy
Maintained
$ 42.00
+3.1%
08/12/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/15/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
$ 50.00
+22.8%
04/30/2026
Les Sulewski
Truist Financial
Buy
Reiterated
$ 45.00
+10.5%
04/30/2026
Last report
2026 оны 7-р сарын 29
Fiscal period
Q2 2026
$ 0.02 / $ 0.11
-81.46%miss
Revenue / Est. (USD)
4.14 тэрбум / 4.03 тэрбум
+2.79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
4.48 тэрбум
4.71 тэрбум
3.98 тэрбум
4.14 тэрбум
Cost of goods sold
2.18 тэрбум
2.06 тэрбум
2.01 тэрбум
1.99 тэрбум
Cost of revenue
2.18 тэрбум
2.06 тэрбум
2.01 тэрбум
1.99 тэрбум
Research and development expenses
256.00 сая
267.00 сая
222.00 сая
970.00 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973.00 сая
1.12 тэрбум
1.00 тэрбум
1.03 тэрбум
Operating expense
1.24 тэрбум
1.37 тэрбум
1.21 тэрбум
1.99 тэрбум
Total operating expenses
3.41 тэрбум
3.43 тэрбум
3.22 тэрбум
3.98 тэрбум
Operating income
1.07 тэрбум
1.28 тэрбум
763.00 сая
167.00 сая
Other non operating income
-27.00 сая
-
-13.00 сая
-69.00 сая
EBT including unusual items
648.00 сая
90.00 сая
436.00 сая
-455.00 сая
EBT excluding unusual items
832.00 сая
1.08 тэрбум
547.00 сая
-57.00 сая
Income tax expense
214.00 сая
-390.00 сая
67.00 сая
121.00 сая
Effective tax rate
33.02%
-433.33%
15.37%
-26.59%
Other operating expenses
9.00 сая
-17.00 сая
-14.00 сая
-18.00 сая
Net income
433.00 сая
480.00 сая
369.00 сая
-576.00 сая
Net profit margin
9.67%
10.19%
9.27%
-13.91%
Earnings per share
0.78
0.96
0.53
0.02
Interest and investment income
-
92.00 сая
-
-
Interest expense
-205.00 сая
-280.00 сая
-191.00 сая
-186.00 сая
Net interest expenses
-205.00 сая
-188.00 сая
-191.00 сая
-186.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
1.32 тэрбум
1.54 тэрбум
1.00 тэрбум
408.00 сая
Gain or loss from assets sale
-
-
-8.00 сая
-12.00 сая
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс